Actelion Ltd - Product Pipeline Review - 2016

  • ID: 3691132
  • Company Profile
  • 74 pages
  • Global Markets Direct
  • Actelion Pharmaceuticals Ltd.
1 of 4
Actelion Ltd - Product Pipeline Review - 2016

Summary

‘Actelion Ltd - Product Pipeline Review - 2016’, provides an overview of the Actelion Ltd’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Actelion Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Actelion Ltd
- The report provides overview of Actelion Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Actelion Ltd’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Actelion Ltd’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Actelion Ltd’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Actelion Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Actelion Ltd’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Actelion Ltd Snapshot

Actelion Ltd Overview

Key Information

Key Facts

Actelion Ltd - Research and Development Overview

Key Therapeutic Areas

Actelion Ltd - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Actelion Ltd - Pipeline Products Glance

Actelion Ltd - Late Stage Pipeline Products

Pre-Registration Products/Combination Treatment Modalities

Phase III Products/Combination Treatment Modalities

Actelion Ltd - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Actelion Ltd - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Actelion Ltd - Drug Profiles

mechlorethamine hydrochloride

Product Description

Mechanism of Action

R&D Progress

selexipag

Product Description

Mechanism of Action

R&D Progress

cadazolid

Product Description

Mechanism of Action

R&D Progress

macitentan

Product Description

Mechanism of Action

R&D Progress

ponesimod

Product Description

Mechanism of Action

R&D Progress

miglustat

Product Description

Mechanism of Action

R&D Progress

clazosentan

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Antagonize Endothelin Receptor A and Endothelin Receptor B for Essential Hypertension

Product Description

Mechanism of Action

R&D Progress

Cenerimod

Product Description

Mechanism of Action

R&D Progress

AC-082

Product Description

Mechanism of Action

R&D Progress

ACT-451840

Product Description

Mechanism of Action

R&D Progress

ACT-541468

Product Description

Mechanism of Action

R&D Progress

lucerastat

Product Description

Mechanism of Action

R&D Progress

Small Molecule 2 for Neurological Disorders

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Cardiovascular Disorders

Product Description

Mechanism of Action

R&D Progress

AC-080

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Antagonize Orexin 2 Receptor for Sleep Disorders

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit DNA Gyrase and Topoisomerase IV for Bacterial Infection

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Hypertension

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Antagonize Endothelin A Receptor for Hypertension

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit DNA Ligase for Staphylococcal Infections

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Cancer

Product Description

Mechanism of Action

R&D Progress

Actelion Ltd - Pipeline Analysis

Actelion Ltd - Pipeline Products by Target

Actelion Ltd - Pipeline Products by Route of Administration

Actelion Ltd - Pipeline Products by Molecule Type

Actelion Ltd - Pipeline Products by Mechanism of Action

Actelion Ltd - Recent Pipeline Updates

Actelion Ltd - Dormant Projects

Actelion Ltd - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

almorexant

selexipag

Actelion Ltd - Company Statement

Actelion Ltd - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Actelion Ltd, Key Information

Actelion Ltd, Key Facts

Actelion Ltd - Pipeline by Indication, 2016

Actelion Ltd - Pipeline by Stage of Development, 2016

Actelion Ltd - Monotherapy Products in Pipeline, 2016

Actelion Ltd - Partnered Products in Pipeline, 2016

Actelion Ltd - Partnered Products/ Combination Treatment Modalities, 2016

Actelion Ltd - Out-Licensed Products in Pipeline, 2016

Actelion Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016

Actelion Ltd - Pre-Registration, 2016

Actelion Ltd - Phase III, 2016

Actelion Ltd - Phase II, 2016

Actelion Ltd - Phase I, 2016

Actelion Ltd - Preclinical, 2016

Actelion Ltd - Discovery, 2016

Actelion Ltd - Pipeline by Target, 2016

Actelion Ltd - Pipeline by Route of Administration, 2016

Actelion Ltd - Pipeline by Molecule Type, 2016

Actelion Ltd - Pipeline Products by Mechanism of Action, 2016

Actelion Ltd - Recent Pipeline Updates, 2016

Actelion Ltd - Dormant Developmental Projects,2016

Actelion Ltd - Discontinued Pipeline Products, 2016

Actelion Ltd, Subsidiaries

List of Figures

Actelion Ltd - Pipeline by Top 10 Indication, 2016

Actelion Ltd - Pipeline by Stage of Development, 2016

Actelion Ltd - Monotherapy Products in Pipeline, 2016

Actelion Ltd - Partnered Products in Pipeline, 2016

Actelion Ltd - Pipeline by Top 10 Target, 2016

Actelion Ltd - Pipeline by Route of Administration, 2016

Actelion Ltd - Pipeline by Molecule Type, 2016

Actelion Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll